On September 24, 2019 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported its participation at two upcoming healthcare investor conferences in October (Press release, Calithera Biosciences, SEP 24, 2018, View Source [SID1234535236]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald Global Healthcare Conference. On Tuesday, October 2, 2018, Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer will present a corporate update at 9:10 a.m. EDT at the
Cantor Fitzgerald Global Healthcare Conference in New York City.

Leerink Partners Rare Disease & Oncology Roundtable. On Wednesday, October 3, 2018, Susan M. Molineaux, Ph.D., the company’s Founder, President and Chief Executive Officer will participate in a fireside chat to discuss immunooncology at the Leerink Partners Rare Disease & Oncology Roundtable being held in New York City at 8:30 a.m. EDT.